Search Results

Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced positive results from its first-in-human CLOT OUT clinical trial evaluating the safety and performance of its Clotild® Smart Guidewire System used during mechanical thrombectomy treating ischemic stroke.

Sensome announced today enrollment of the first patients into a feasibility clinical study using the Clotild ® Smart Guidewire in peripheral artery disease (PAD).

Pioneering smart medical device company, Sensome, and world-leading Japanese guidewire company, Asahi Intecc, are announcing a collaboration to develop the next generation Clotild® Smart Guidewire, with Asahi Intecc taking on the manufacturing role for this groundbreaking device destined for the treatment of acute ischemic stroke.

Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced that it has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health of the Food and Drug Administration for its Clotild® Smart Guidewire System designed to improve the treatment of ischemic stroke patients.

The two companies start development program to integrate Sensome’s tissue micro-sensor into Asahi’s world class guidewire

The industry analysis report is considered a valuable source of information about the global Interventional Neurology Device industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.